EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study

Juno Kim, Sung Jin Lee, Tae Kwann Park, Hae Jung Sun, Hoon Dong Kim, In Hwan Cho, Jung Woo Han, Kyung Seek Choi

Korean Journal of Ophthalmology · 2023

DOI: 10.3341/kjo.2023.0009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Korean Journal of Ophthalmology, 2023. Verfasst von Juno Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Visual Acuity, Wet Macular Degeneration. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Soonchunhyang University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To compare short-term efficacy and safety of intravitreal brolucizumab injection with aflibercept in treatment-naive neovascular age-related macular degeneration (nAMD) patients.

Methods

A total of 59 eyes from 59 treatment-naive nAMD patients in three hospitals were retrospectively reviewed. Of which, 27 patients underwent intravitreal brolucizumab injections and 32 received aflibercept. After monthly consecutive three injections, best-corrected visual acuity (BCVA; in logarithm of minimal angle of resolution [logMAR]), central macular thickness (CMT), dry macula achievement rate, and intraocular inflammation (IOI) incidence were compared.

Results

After loading-phase treatment, BCVA was significantly increased from 0.48 ± 0.30 logMAR at baseline to 0.33 ± 0.21 logMAR at 3 months in the brolucizumab group (p = 0.002) and 0.40 ± 0.39 logMAR at baseline to 0.33 ± 0.36 logMAR at 3 months in the aflibercept group (p = 0.007). But there was no significant difference in BCVA improvement at 3 months between the two groups. CMT significantly decreased from 429.67 ± 250.59 μm at baseline to 210.67 ± 93.53 μm at 3 months in the brolucizumab group and from 346.69 ± 159.09 μm to 234.52 ± 83.42 μm in the aflibercept group (both p < 0.001). The amount of CMT reduction was significantly greater in the brolucizumab group after 3 months (p = 0.036). In typical AMD eyes, brolucizumab showed similar BCVA improvement but better CMT reduction at 3 months (p = 0.018). Dry macula achievement rate was not significantly different between the two groups. One IOI was observed in the brolucizumab group.

Conclusions

Intravitreal injections of brolucizumab and aflibercept showed similar anatomical and functional outcomes. But CMT reduction was greater in the brolucizumab group. One IOI was identified, which was tolerable for topical agents. These results suggest that brolucizumab could be a novel first line treatment option for treating naive nAMD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedVisual AcuityWet Macular DegenerationAgedAged, 80 and overFemaleHumansMaleMiddle AgedAngiogenesis InhibitorsFluorescein AngiographyFollow-Up StudiesFundus OculiIntravitreal InjectionsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetrospective StudiesTime FactorsTomography, Optical CoherenceTreatment Outcome

Stichwörter der Autor:innen

BrolucizumabIntraocular inflammationIntravitreal injectionsMacular degeneration

Substanzen

afliberceptAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedbrolucizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Ophthalmology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
  • Department of Ophthalmology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • Department of Ophthalmology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.

Förderung

  • Soonchunhyang University

Zitieren

APA

Kim, J., Lee, S. J., Park, T. K., Sun, H. J., Kim, H. D., Cho, I. H., Han, J. W., & Choi, K. S. (2023). Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study. Korean Journal of Ophthalmology. https://doi.org/10.3341/kjo.2023.0009

Vancouver

Kim J, Lee SJ, Park TK, Sun HJ, Kim HD, Cho IH, et al. Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study. Korean Journal of Ophthalmology. 2023. doi:10.3341/kjo.2023.0009

BibTeX
@article{Kim2023,
  author = {Kim, Juno and Lee, Sung Jin and Park, Tae Kwann and Sun, Hae Jung and Kim, Hoon Dong and Cho, In Hwan and Han, Jung Woo and Choi, Kyung Seek},
  title = {Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study},
  journal = {Korean Journal of Ophthalmology},
  year = {2023},
  doi = {10.3341/kjo.2023.0009}
}
Kostenlos starten →